Enliven Therapeutics, Inc.

As of October 31, 2025, Enliven Therapeutics, Inc. shows a bullish technical trend, with mixed indicators including a bullish weekly MACD and bearish weekly Bollinger Bands, while underperforming the S&P 500 over the past year and year-to-date.

As of October 31, 2025, Enliven Therapeutics, Inc. shows a bullish trend supported by strong indicators, despite some caution from mildly bearish KST signals and a longer-term underperformance compared to the S&P 500.

As of October 3, 2025, Enliven Therapeutics, Inc. has a bearish trend with weak MACD signals and underperformed the S&P 500 by -26.26%, indicating a negative outlook in the near term.

As of October 3, 2025, Enliven Therapeutics, Inc. is in a bearish trend, supported by negative technical indicators and underperformance compared to the S&P 500, with year-to-date returns of -12.84% versus 14.18% for the index.

As of September 26, 2025, Enliven Therapeutics, Inc. shows a mildly bearish trend due to negative MACD readings and underperformance against the S&P 500 in the short term, despite a strong 848.34% return over the past three years.

As of September 26, 2025, Enliven Therapeutics, Inc. shows a mildly bearish trend with recent performance of +5.54% over the past week, but has underperformed the S&P 500 year-to-date with -11.07%.

As of September 26, 2025, Enliven Therapeutics, Inc. shows a mildly bearish trend with recent performance indicating a 5.54% weekly gain, but a year-to-date decline of -11.07%, significantly underperforming the S&P 500.

As of September 11, 2025, Enliven Therapeutics, Inc. has a mildly bearish technical outlook, with bearish indicators from MACD, moving averages, and Bollinger Bands, and has underperformed the S&P 500 year-to-date and over the past year.

As of June 13, 2025, Enliven Therapeutics, Inc. shows a neutral trend with mixed signals, as weekly indicators are mildly bullish while monthly indicators remain bearish, indicating a lack of strong directional momentum.

As of March 2022, the management team of Enliven Therapeutics, Inc. includes Independent Chairman Mr. David Mott, President and CEO Dr. Rahul Ballal, and several independent directors: Mr. Edward Conner, Ms. Mette Agger, Dr. David Bonita, Mr. Mark Chin, and Dr. Barbara Dalton.

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare inherited genetic disorders of hemoglobin. It has a market cap of approximately $1.07 billion and reported a net profit loss of $29 million as of March 2025.

As of Jun 18, Enliven Therapeutics, Inc. has a market capitalization of 1,069.71 million, with net sales of 0.00 million and a net profit of -94.83 million over the latest four quarters. The company reported shareholder's funds of 309.85 million and total assets of 325.76 million as of Dec 24.